User login
Key clinical point: The combination of oral abrocitinib and topical therapy was effective and well tolerated in adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: At week 12, a significantly higher proportion of patients treated with abrocitinib 200 mg or 100 mg vs placebo achieved an Investigator’s Global Assessment response of 0/1 (46.2% and 41.6% vs 24.5%) and 75% or more improvement in Eczema Area and Severity Index (72.0% and 68.5% vs 41.5%; P < .05 for all). Serious adverse events were reported by less than 3% of patients.
Study details: Findings are from JADE TEEN, a phase 3 trial including 285 adolescents with moderate-to-severe AD and an inadequate response to topical medication or in need for systemic therapy, who were randomly assigned to receive once-daily oral abrocitinib, 200 mg or 100 mg, or placebo for 12 weeks in combination with topical therapy.
Disclosures: This study was funded by Pfizer Inc. The authors declared receiving nonfinancial support, grants, and personal fees from several sources including Pfizer. Four authors reported being employees and/or shareholders of Pfizer.
Source: Eichenfield LF et al. JAMA Dermatol. 2021 Aug 18. doi: 10.1001/jamadermatol.2021.2830.
Key clinical point: The combination of oral abrocitinib and topical therapy was effective and well tolerated in adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: At week 12, a significantly higher proportion of patients treated with abrocitinib 200 mg or 100 mg vs placebo achieved an Investigator’s Global Assessment response of 0/1 (46.2% and 41.6% vs 24.5%) and 75% or more improvement in Eczema Area and Severity Index (72.0% and 68.5% vs 41.5%; P < .05 for all). Serious adverse events were reported by less than 3% of patients.
Study details: Findings are from JADE TEEN, a phase 3 trial including 285 adolescents with moderate-to-severe AD and an inadequate response to topical medication or in need for systemic therapy, who were randomly assigned to receive once-daily oral abrocitinib, 200 mg or 100 mg, or placebo for 12 weeks in combination with topical therapy.
Disclosures: This study was funded by Pfizer Inc. The authors declared receiving nonfinancial support, grants, and personal fees from several sources including Pfizer. Four authors reported being employees and/or shareholders of Pfizer.
Source: Eichenfield LF et al. JAMA Dermatol. 2021 Aug 18. doi: 10.1001/jamadermatol.2021.2830.
Key clinical point: The combination of oral abrocitinib and topical therapy was effective and well tolerated in adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: At week 12, a significantly higher proportion of patients treated with abrocitinib 200 mg or 100 mg vs placebo achieved an Investigator’s Global Assessment response of 0/1 (46.2% and 41.6% vs 24.5%) and 75% or more improvement in Eczema Area and Severity Index (72.0% and 68.5% vs 41.5%; P < .05 for all). Serious adverse events were reported by less than 3% of patients.
Study details: Findings are from JADE TEEN, a phase 3 trial including 285 adolescents with moderate-to-severe AD and an inadequate response to topical medication or in need for systemic therapy, who were randomly assigned to receive once-daily oral abrocitinib, 200 mg or 100 mg, or placebo for 12 weeks in combination with topical therapy.
Disclosures: This study was funded by Pfizer Inc. The authors declared receiving nonfinancial support, grants, and personal fees from several sources including Pfizer. Four authors reported being employees and/or shareholders of Pfizer.
Source: Eichenfield LF et al. JAMA Dermatol. 2021 Aug 18. doi: 10.1001/jamadermatol.2021.2830.